Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Mitglied/er, Innere Klinik (Tumorforschung)
Aktuelle Veranstaltungen
-
2024 WS
- Blockpraktikum Innere Medizin (PV)
- Vorlesung Prävention, Gesundheitsförderung (WA)
- Kurs der allgemeinen klinischen Untersuchungen (PV)
- Tumorkonferenz (3. klinischer Studienabschnitt)
- Integriertes Seminar klinische Untersuchungen (1. Abschnitt der Ärztlichen Ausbildung) (nur Wintersemester) (PV)
- Hämatologisches und onkologisches Mittagsseminar
- Querschnittsbereich "Prävention/Gesundheitsförderung"
- Seminar für Studierende im Praktischen Jahr
- Differentialdiagnose Innere Krankheiten
- Öffentliches Tumorboard Lungenkrebszentrum
Vergangene Veranstaltungen (max. 10)
-
2024 SS
- Hämatologisches und onkologisches Mittagsseminar
- Tumorkonferenz (3. klinischer Studienabschnitt)
- Kurs der allgemeinen klinischen Untersuchungen (PV)
- Blockpraktikum Innere Medizin (PV)
- Vorlesung Prävention, Gesundheitsförderung (WA)
- Differentialdiagnose Innere Krankheiten
- Querschnittsbereich "Prävention/Gesundheitsförderung"
- Seminar für Studierende im Praktischen Jahr
- Öffentliches Tumorboard Lungenkrebszentrum
-
2023 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapyIn: Scientific Reports Jg. 14 (2024) Nr. 1, 13765Online Volltext: dx.doi.org/ (Open Access)
-
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)In: JTO Clinical and Research Reports Jg. 5 (2024) Nr. 4, 100626Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein-Directed Imaging Outperforms ¹⁸F-FDG PET/CT in Malignant Mesothelioma : A Prospective, Single-Center, Observational TrialIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 8, S. 1188 - 1193Online Volltext: dx.doi.org/
-
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment : Comparison with Stage III DiseaseIn: Cancers Jg. 16 (2024) Nr. 6, 1174Online Volltext: dx.doi.org/ (Open Access)
-
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic : Real-world data from the German prospective CRISP Registry (AIO-TRK-0315)In: International Journal of Cancer Jg. 154 (2024) Nr. 11, S. 1967 - 1978Online Volltext: dx.doi.org/ (Open Access)
-
Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE)In: International Journal of Cancer (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
The Incidence of Distant Metastases in Patients with Pleural Mesothelioma Screened for a Multimodal Approach : How Much Staging Do We Really Need?In: Cancers Jg. 16 (2024) Nr. 10, 1917Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Theranostics with somatostatin receptor antagonists in SCLC : Correlation of 68Ga-SSO120 PET with immunohistochemistry and survivalIn: Theranostics Jg. 14 (2024) Nr. 14, S. 5400 - 5412Online Volltext: dx.doi.org/ (Open Access)
-
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients : A Single-Center Retrospective StudyIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 10, S. 1540 - 1549Online Volltext: dx.doi.org/
-
Accuracy of nodal staging by 18F-FDG-PET/CT in limited disease small-cell lung cancerIn: Asian Cardiovascular and Thoracic Annals Jg. 31 (2023) Nr. 6, S. 506 - 511Online Volltext: dx.doi.org/ (Open Access)
-
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world settingIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 11, S. 9243 - 9252Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic factors in nonsmall cell lung cancer : insights from the German CRISP registryIn: European Respiratory Journal (ERJ) Jg. 61 (2023) Nr. 2, 2201336Online Volltext: dx.doi.org/ (Open Access)
-
Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms : Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft – KurzfassungIn: Pneumologie Jg. 77 (2023) Nr. 10, S. 671 - 813Online Volltext: dx.doi.org/
-
SUVmₐₓ Above 20 in ¹⁸F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown PrimaryIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 8, S. 1191 - 1194Online Volltext: dx.doi.org/
-
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer : focus on treatment selection and prognostic factorsIn: Immunotherapy Jg. 14 (2022) Nr. 12, S. 927 - 944Online Volltext: dx.doi.org/ (Open Access)
-
Konzepte beim oligometastasierten LungenkarzinomIn: Die Onkologie Jg. 28 (2022) Nr. 12, S. 1078 - 1086Online Volltext: dx.doi.org/
-
Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatmentIn: Radiation Oncology Jg. 17 (2022) Nr. 1, 126Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CTIn: Scientific Reports Jg. 12 (2022) Nr. 1, 17511Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implicationsIn: Lung Cancer Jg. 168 (2022) S. 10 - 20Online Volltext: dx.doi.org/
-
Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatmentIn: European Journal of Cardio-Thoracic Surgery Jg. 61 (2022) Nr. 2, S. 269 - 276Online Volltext: dx.doi.org/ (Open Access)
-
Therapie früher und lokal fortgeschrittener Stadien des nicht-kleinzelligen LungenkarzinomsIn: Die Innere Medizin Jg. 63 (2022) Nr. 7, S. 717 - 723Online Volltext: dx.doi.org/
-
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerIn: Therapeutic Advances in Medical Oncology Jg. 13 (2021)Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V⁶⁰⁰-mutated Squamous Cell Lung Cancer : Concurrent Evolvement of PTEN and MEK1 MutationsIn: Clinical Lung Cancer Jg. 22 (2021) Nr. 5, S. E668 - E672Online Volltext: dx.doi.org/
-
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapyIn: European Journal of Cancer (EJC) Jg. 149 (2021) S. 211 - 221Online Volltext: dx.doi.org/
-
Biomarker testing in non-small cell lung cancer in routine care : Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)In: Lung Cancer Jg. 152 (2021) S. 174 - 184Online Volltext: dx.doi.org/ (Open Access)
-
Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapyIn: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. 3, S. 002262Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184In: Lung Cancer Jg. 157 (2021) S. 167Online Volltext: dx.doi.org/ (Open Access)
-
DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patientsIn: European Journal of Cancer (EJC) Jg. 147 (2021) S. 142 - 150Online Volltext: dx.doi.org/
-
Die aktuelle Therapie des asbestassoziierten malignen Pleuramesothelioms - Ein Experten-KonsensuspapierIn: Pneumologie Jg. 75 (2021) Nr. 10, S. 776 - 794Online Volltext: dx.doi.org/ (Open Access)
-
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung CancerIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 7, S. 723 - 733Online Volltext: dx.doi.org/ (Open Access)
-
Impact of EBUS-TBNA in addition to [¹⁸F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLCIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) S. 2894 - 2903Online Volltext: dx.doi.org/ (Open Access)
-
KRAS G12C-mutated advanced non-small cell lung cancer : A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)In: Lung Cancer Jg. 154 (2021) S. 51 - 61Online Volltext: dx.doi.org/ (Open Access)
-
N-staging in large cell neuroendocrine carcinoma of the lung : diagnostic value of [¹⁸F]FDG PET/CT compared to the histopathology reference standardIn: EJNMMI Research Jg. 11 (2021) Nr. 1, 68Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Neoadjuvant and adjuvant end-points in health technology assessment in oncologyIn: European Journal of Cancer (EJC) Jg. 147 (2021) S. 40 - 50Online Volltext: dx.doi.org/
-
Patterns of nodal spread in stage III NSCLC : Importance of EBUS-TBNA and ¹⁸F-FDG PET/CT for radiotherapy target volume definitionIn: Radiation Oncology Jg. 16 (2021) Nr. 1, 176Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non-Small Cell Lung Cancer Patients Receiving Definitive ChemoradiotherapyIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 12, S. 1684 - 1691Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
A novel epitope quality-based immune escape mechanism reveals patient’s suitability for immune checkpoint inhibitionIn: Cancer Management and Research Jg. 12 (2020) S. 7881 - 7890Online Volltext: dx.doi.org/ (Open Access)
-
Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutationIn: Lung Cancer Jg. 139 (2020) S. 165 - 168Online Volltext: dx.doi.org/
-
Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment : Only few risks left to improveIn: European Journal of Cancer (EJC) Jg. 138 (2020) S. 156 - 168Online Volltext: dx.doi.org/
-
ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancerIn: Lung Cancer Jg. 149 (2020) S. 10 - 16Online Volltext: dx.doi.org/
-
HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma modelIn: Lung Cancer Jg. 144 (2020) S. 20 - 29Online Volltext: dx.doi.org/
-
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesotheliomaIn: Scientific Reports Jg. 10 (2020) Nr. 1, S. 18677Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression contextIn: European Journal of Cancer (EJC) Jg. 140 (2020) S. 76 - 85Online Volltext: dx.doi.org/
-
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesotheliomaIn: Cancer Management and Research Jg. 11 (2019) S. 8711 - 8720Online Volltext: dx.doi.org/ (Open Access)
-
Cerebral Recurrence after trimodal Therapy of Patients with locally advanced NSCLC - Prognostic Factors and prognostic ImportanceIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 195 (2019) Nr. Suppl. 1, S. S66 - S67
-
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitroIn: BMC Cancer Jg. 19 (2019) Nr. 1, 108Online Volltext: dx.doi.org/ (Open Access)
-
Implementation of lung cancer screening in Europe: Challenges and potential solutions : Summary of a multidisciplinary roundtable discussionIn: ESMO Open Jg. 4 (2019) Nr. 5, S. 000577Online Volltext: dx.doi.org/ (Open Access)
-
Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancerIn: Annals of Oncology Jg. 30 (2019) Nr. 4, S. 655 - 657Online Volltext: dx.doi.org/ (Open Access)
-
Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules : analysis of the ESPATUE randomized phase 3 trialIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 46 (2019) Nr. 7, S. 1439 - 1447Online Volltext: dx.doi.org/
-
Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based ChemotherapyIn: Journal of Oncology (2019) 2902985Online Volltext: dx.doi.org/ (Open Access)
-
Aktueller Stand der Diagnostik und Therapie des nichtkleinzelligen Lungenkarzinoms (NSCLC) im Stadium IIIIn: Der Onkologe Jg. 24 (2018) Nr. 12, S. 974 - 982Online Volltext: dx.doi.org/
-
Brain metastases in ALK-positive NSCLC - Time to adjust current treatment algorithmsIn: OncoTarget Jg. 9 (2018) Nr. 80, S. 35181 - 35194Online Volltext: dx.doi.org/ (Open Access)
-
Clinical implications of the innovations in the primary tumour and metastasis of the 8th edition of the TNM classification for lung cancerIn: Journal of Thoracic Disease Jg. 10 (2018) Nr. Suppl. 22, S. S2682 - S2685Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung CancerIn: Journal of Thoracic Oncology Jg. 13 (2018) Nr. 12, S. 1818 - 1831Online Volltext: dx.doi.org/ (Open Access)
-
Eighth edition staging of thoracic malignancies : Implications for the reporting pathologistIn: Archives of Pathology and Laboratory Medicine Jg. 142 (2018) Nr. 5, S. 645 - 661Online Volltext: dx.doi.org/ (Open Access)
-
Final Re-irradiation of Patients with NSCLC after primary high-dose Local TherapyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 194 (2018) Nr. Suppl.1, S. S59Online Volltext: dx.doi.org/ (Open Access)
-
Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer typesIn: Biochemical and Biophysical Research Communications (BBRC) Jg. 500 (2018) Nr. 3, S. 621 - 625Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapyIn: OncoTarget Jg. 9 (2018) Nr. 32, S. 22254 - 22268Online Volltext: dx.doi.org/ (Open Access)
-
Inhibition of MDM2 via Nutlin-3A : A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53In: Journal of Oncology (2018) 1986982Online Volltext: dx.doi.org/ (Open Access)
-
Investigations of Long-term Survivors with locally advanced NSCLC on Morbidity of curative Therapy - Analysis of neurocognitive EffectsIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 194 (2018) Nr. Suppl. 1, S. 110Online Volltext: dx.doi.org/ (Open Access)
-
MET Expression in Advanced Non–Small-Cell Lung Cancer : Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and ImmunotherapyIn: Clinical Lung Cancer Jg. 19 (2018) Nr. 4, S. e441 - e463Online Volltext: dx.doi.org/
-
Pre-therapeutic metabolic Tumor Volume (MTV) in (18) F-FDG-PET/CT as a prognostic Factor in Patients with Stage IIIA-IIIB NSCLC before Trimodal Therapy or definitive Chemoradiotherapy - Results of Phase 3 StudyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 194 (2018) Nr. Suppl.1, S. S41 - S42Online Volltext: dx.doi.org/ (Open Access)
-
Pretreatment metabolic volume in PET : Prognostic in lung cancer? German ESPATUE randomised phase3trialIn: Radiotherapy and Oncology (The Green Journal) Jg. 127 (2018) Nr. Suppl.1, S. S253 - S254Online Volltext: dx.doi.org/ (Open Access)
-
Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine TumorsIn: Technology in Cancer Research & Treatment (TCRT) Jg. 17 (2018)Online Volltext: dx.doi.org/ (Open Access)
-
Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung AdenocarcinomaIn: Clinical Lung Cancer Jg. 19 (2018) Nr. 6, S. e879 - e884Online Volltext: dx.doi.org/
-
Sequential Dose Escalation Study NEOAHA for locally advanced NSCLC - Phase I-Results of Stage 1 (Integrated Boost-Radiation in neoadjuvant Therapy)In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 194 (2018) Nr. Suppl. 1, S. S23 - S24Online Volltext: dx.doi.org/ (Open Access)
-
Therapie des nichtkleinzelligen Lungenkarzinoms im Stadium I–IIIC : Multimodale Konzepte mit kurativer IntentionIn: Best Practice Onkologie Jg. 13 (2018) Nr. 3, S. 156 - 169Online Volltext: dx.doi.org/
-
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany : an observational studyIn: BMC Cancer Jg. 18 (2018) S. 135Online Volltext: dx.doi.org/ (Open Access)
-
A Phase II Study Evaluating the Combination of Everolimus with Carboplatin/Paclitaxel as 1st Line Treatment in Patients with Advanced LCNECIn: Journal of Thoracic Oncology Jg. 12 (2017) Nr. 1, Suppl., S. S697Online Volltext: dx.doi.org/
-
Atezolizumab as 1L therapy for advanced NSCLC in PD-L1-selected patients : updated ORR, PFS and OS data from the BIRCH studyIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 5, S. 220Online Volltext: dx.doi.org/
-
Checkpointinhibitoren beim nichtkleinzelligen LungenkarzinomIn: Der Onkologe Jg. 23 (2017) Nr. 10, S. 838 - 844Online Volltext: dx.doi.org/
-
Clinical Research Platform into Molecular Testing, Treatment, Outcome (CRISP) : A Prospective German Registry in Stage IV NSCLC AIO-TRK-0315In: Journal of Thoracic Oncology Jg. 12 (2017) Nr. Suppl. 1, S. S385
-
Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP) : a prospective German Registry in stage IV NSCLC AIO-TRK-0315)In: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5, S. 1385TiP
-
Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma Patients (CRISP) : A prospective German registry in stage IV NSCLC, AIO-TRK-0315In: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 2, S. 125P
-
Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidenceIn: OncoTarget Jg. 8 (2017) Nr. 25, S. 41670 - 41678Online Volltext: dx.doi.org/ (Open Access)
-
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma : A multicenter phase II trialIn: Annals of Oncology Jg. 28 (2017) Nr. 8, S. 1898 - 1902Online Volltext: dx.doi.org/
-
Factors for the long-term Survival of Patients with NSCLC in the Stage of oligometastatic Disease after definitive Local TherapyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 193 (2017) Nr. Suppl. 1, S. 58
-
First signal-finding study of soluble HLA-G and -E (sHLA-G/E) as potential prognostic markers of clinical outcome in advanced, refractory squamous-cell NSCLC (SCC) treated with nivolumab (NIVO) : checkMate 063In: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3, S. 218 - 219Online Volltext: dx.doi.org/
-
Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer : secondary analysis of a randomized trialIn: Annals of Oncology Jg. 28 (2017) Nr. 5, S. 1084 - 1089Online Volltext: dx.doi.org/ (Open Access)
-
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung CancerIn: Journal of Thoracic Oncology Jg. 12 (2017) Nr. 1, S. 54 - 64Online Volltext: dx.doi.org/ (Open Access)
-
Immunonkologie : Die sanfte Revolution der Krebsmedizin?In: Der Onkologe Jg. 23 (2017) Nr. 10, S. 790 - 792Online Volltext: dx.doi.org/
-
Importance of neoadjuvant Radiotherapy in the trimodal Approach in the Treatment of locally advanced, potentially resectable NSCLC - a Meta-AnalysisIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 193 (2017) Nr. Suppl. 1, S. S62 - S63
-
Intermodaler Vergleich von EBUS-TBNA, 18F-FDG PET/CT im Rahmen der Bestrahlungsplanung beim Lokal-fortgeschrittenen Nichtkleinzelligen Lungenkarzinom (Stadium II-IIIB)
23. Jahrestagung der Deutschen Gesellschaft für Radioonkologie ; DEGRO 2017 ; 14. - 18. Juni 2017, Berlin, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 193 (2017) Nr. Suppl. 1: Abstracts DEGRO 2017, S. S20Online Volltext: dx.doi.org/ -
Long-term outcomes with nivolumab in patients with previously treated advanced Non-Small Cell Lung Cancer (NSCLC)In: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3, S. 137Online Volltext: dx.doi.org/
-
Molecular testing, frequency of molecular alterations and first-line treatment of patients with non-small cell lung carcinoma (NSCLC) in Germany. First results from the prospective German Registry CRISP (AIO-TRK-0315)In: Oncology Research and Treatment Jg. 40 (2017) Nr. 3, S. 136 - 136Online Volltext: dx.doi.org/
-
Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer : Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057)In: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 35, S. 3924 - 3933Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Prognostic Significance of Mean Lung Dose (MLD) in the dose-enhanced Radiochemotherapy of Local Advanced NSCLC - Analysis of ESPATU's Definitive Radiochemotherapy ArmIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 193 (2017) Nr. 1, S. 20
-
Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA Specimen of Lung AdenocarcinomaIn: Journal of Thoracic Oncology Jg. 12 (2017) Nr. Suppl. 1, S. S1201 - S1201
-
SELECT-2: A phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancerIn: Annals of Oncology Jg. 28 (2017) Nr. 12, S. 3028 - 3036Online Volltext: dx.doi.org/ (Open Access)
-
Autophagy inhibition upregulates CD4(+) tumor infiltrating lymphocyte expression via miR-155 regulation and TRAIL activationIn: Molecular Oncology Jg. 10 (2016) Nr. 10, S. 1516 - 1531Online Volltext: dx.doi.org/ (Open Access)
-
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patientsIn: Journal of Cancer Research and Clinical Oncology Jg. 142 (2016) Nr. 4, S. 795 - 805Online Volltext: dx.doi.org/
-
Exonabhängige Subgruppenanalyse der nicht-interventionellen REASON-Studie : PFS und OS beim EGFR-mutierten NSCLC mit Behandlung von Gefitinib versus ChemotherapieIn: Pneumologie Jg. 70 (2016) Nr. 8, S. 514 - 521Online Volltext: dx.doi.org/
-
NEOliquid : Detection of KIF5B-RET fusions in liquid biopsy samplesIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. Suppl. 4, S. 82 - 83Online Volltext: dx.doi.org/
-
Reply to the Letter to the Editor by Hendriks et al.In: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 3, S. e43 - e44Online Volltext: dx.doi.org/ (Open Access)
-
Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment : Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung CancerIn: Journal of Clinical Oncology (JCO) Jg. 34 (2016) Nr. 21, S. 2526 - 2533Online Volltext: dx.doi.org/
-
Subgruppenanalyse aus der nicht-interventionellen Beobachtungsstudie REASON : PFS und OS gemäß Alter, Raucherstatus, Geschlecht und histologischem Subtyp unter Verwendung von Gefitinib bzw. chemotherapeutischer Behandlung bei NSCLC-PatientenIn: Pneumologie Jg. 70 (2016) Nr. 9, S. 579 - 588Online Volltext: dx.doi.org/
-
The IASLC Lung Cancer Staging Project : Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM ClassificationIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 5, S. 639 - 650Online Volltext: dx.doi.org/
-
The IASLC Lung Cancer Staging Project : Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung CancerIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 8, S. 1204 - 1223Online Volltext: dx.doi.org/ (Open Access)
-
The IASLC Lung Cancer Staging Project : Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung CancerIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 5, S. 681 - 692Online Volltext: dx.doi.org/
-
The IASLC Lung Cancer Staging Project : Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 1, S. 39 - 51Online Volltext: dx.doi.org/ (Open Access)
-
The IASLC Mesothelioma Staging Project : Improving Staging of a Rare Disease Through International ParticipationIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 12, S. 2082 - 2088Online Volltext: dx.doi.org/
-
The IASLC Mesothelioma Staging Project : Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural MesotheliomaIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 12, S. 2089 - 2099Online Volltext: dx.doi.org/ (Open Access)
-
The IASLC lung cancer staging project : Background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancerIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 5, S. 651 - 665Online Volltext: dx.doi.org/
-
The International Association for the Study of Lung Cancer Lung Cancer Staging Project : Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung CancerIn: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 3, S. 300 - 311Online Volltext: dx.doi.org/ (Open Access)
-
Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)In: Journal of Thoracic Oncology Jg. 11 (2016) Nr. 1, S. 85 - 93Online Volltext: dx.doi.org/ (Open Access)
-
16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)In: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. Suppl. 3, S. S717 - S718Online Volltext: dx.doi.org/
-
2nd ESMO Consensus Conference in Lung Cancer : locally advanced stage III non-small-cell lung cancerIn: Annals of Oncology Jg. 26 (2015) Nr. 8, S. 1573 - 1588Online Volltext: dx.doi.org/ (Open Access)
-
A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC)In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 8009Online Volltext: dx.doi.org/ Online Volltext
-
Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomyIn: Journal of Thoracic Disease Jg. 7 (2015) Nr. 3, S. 264 - 272Online Volltext: dx.doi.org/
-
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT) : A Randomized, Double-Blind, Phase III TrialIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 34, S. 4007 - 4014Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Common and rare EGFR mutations (EGFRm) in the RADIANT trial : Final follow-up with 5 year dataIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 7539Online Volltext: dx.doi.org/
-
Concurrent chemoradiotherapy in stage III non-small-cell lung cancer : what is the best regimen?In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 6, S. 532 - 533Online Volltext: dx.doi.org/
-
EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany : An observational studyIn: Cancer Epidemiology, Biomarkers & Prevention Jg. 24 (2015) Nr. 8, S. 1254 - 1261Online Volltext: dx.doi.org/ (Open Access)
-
Final follow-up (f/u) results from RADIANT : A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 7540Online Volltext: dx.doi.org/ Online Volltext
-
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinomaIn: British Journal of Cancer (BJC) Jg. 113 (2015) Nr. 1, S. 12 - 19Online Volltext: dx.doi.org/ (Open Access)
-
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomasIn: Lung Cancer Jg. 88 (2015) Nr. 1, S. 34 - 41Online Volltext: dx.doi.org/
-
Multimodal treatment of non-small-cell lung cancerIn: Lancet Jg. 386 (2015) Nr. 9998, S. 1018 - 1020Online Volltext: dx.doi.org/
-
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerIn: The New England Journal of Medicine Jg. 373 (2015) Nr. 2, S. 123 - 135Online Volltext: dx.doi.org/
-
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patientIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 8051Online Volltext: dx.doi.org/ Online Volltext
-
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 35, S. 4194 - 4201Online Volltext: dx.doi.org/
-
Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factorsIn: BMC Cancer Jg. 15 (2015) Nr. 1, S. 363Online Volltext: dx.doi.org/ (Open Access)
-
Reply to D.A. Palma et al and A. Addeo et alIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 26, S. 2929 - 2930Online Volltext: dx.doi.org/
-
The IASLC Lung Cancer Staging Project : Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung CancerIn: Journal of Thoracic Oncology Jg. 10 (2015) Nr. 11, S. 1515 - 1522Online Volltext: dx.doi.org/ (Open Access)
-
The IASLC lung cancer staging project : Proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancerIn: Journal of Thoracic Oncology Jg. 10 (2015) Nr. 7, S. 990 - 1003Online Volltext: dx.doi.org/ (Open Access)
-
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014) : a phase 3, double-blind, randomised, placebo-controlled trialIn: The Lancet Oncology Jg. 16 (2015) Nr. 4, S. 447 - 456Online Volltext: dx.doi.org/
-
2nd ESMO consensus conference on lung cancer : Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-upIn: Annals of Oncology Jg. 25 (2014) Nr. 8, S. 1462 - 1474Online Volltext: dx.doi.org/ (Open Access)
-
A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC) : RADIANT resultsIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 7501Online Volltext: dx.doi.org/
-
Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trialIn: Journal of Clinical Oncology (JCO) Jg. 32 S (2014) Nr. 15, S. 7513Online Volltext: dx.doi.org/
-
Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC) : RADIANT trialIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 7535Online Volltext: dx.doi.org/
-
Assessment of Folate Receptor-α and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non–Small-Cell Lung Cancer PatientsIn: Clinical Lung Cancer Jg. 15 (2014) Nr. 5, S. 320 - 330.e3Online Volltext: dx.doi.org/
-
Benefits and Risks of Lung Cancer ScreeningIn: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 3, S. 58 - 66Online Volltext: dx.doi.org/
-
Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancerIn: Future Oncology Jg. 10 (2014) Nr. 5, S. 823 - 833Online Volltext: dx.doi.org/
-
Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancerIn: Investigational New Drugs: The Journal of New Anticancer Agents Jg. 32 (2014) Nr. 1, S. 123 - 134Online Volltext: dx.doi.org/
-
Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancerIn: Respiration: International Journal of Thoracic Medicine Jg. 87 (2014) Nr. 3, S. 204 - 210Online Volltext: dx.doi.org/
-
Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagusIn: Diseases of the Esophagus Jg. 27 (2014) Nr. 7, S. 678 - 684Online Volltext: dx.doi.org/
-
Molekulargenetische Untersuchungen bei fortgeschrittenem nicht-kleinzelligem Lungenkarzinom : praktische RelevanzIn: Deutsche Medizinische Wochenschrift - DMW Jg. 139 (2014) Nr. 41, S. 2096 - 2100Online Volltext: dx.doi.org/
-
Ocular toxicities observed with MEK inhibitor RO4987655 (CH4987655) in a single agent phase I study with extension in patients with advanced solid tumorsIn: British Journal of Clinical Pharmacology (BJCP) Jg. 78 (2014) Nr. 4, S. 769Online Volltext: dx.doi.org/
-
Oligometastasiertes Lungenkarzinom : Neue prognoserelevante KonzepteIn: Der Onkologe Jg. 20 (2014) Nr. 10, S. 991 - 997Online Volltext: dx.doi.org/
-
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsIn: Clinical Cancer Research Jg. 20 (2014) Nr. 16, S. 4251 - 4261Online Volltext: dx.doi.org/
-
Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIIb (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE)In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 7510Online Volltext: dx.doi.org/
-
Resection of a Giant Neuroblastoma Misdiagnosed as Atypical Mediastinal CarcinoidIn: Journal of Thoracic Oncology Jg. 9 (2014) Nr. 1, S. 132 - 134Online Volltext: dx.doi.org/
-
Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvementsIn: Current Opinion in Oncology Jg. 26 (2014) Nr. 2, S. 171 - 181Online Volltext: dx.doi.org/
-
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START) : A randomised, double-blind, phase 3 trialIn: The Lancet Oncology Jg. 15 (2014) Nr. 1, S. 59 - 68Online Volltext: dx.doi.org/ (Open Access)
-
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL)In: Lung Cancer Jg. 82 (2013) Nr. 1, S. 83 - 89Online Volltext: dx.doi.org/
-
Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer : Markedly higher rate of pathologic complete remissions than with conventional fractionationIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. 9, S. 2107 - 2115Online Volltext: dx.doi.org/
-
EGFR mutation and management of advanced non-small cell lung cancer (NSCLC) adenocarcinoma in Germany and FranceIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. Suppl. 2, S. 817Online Volltext: dx.doi.org/
-
ERCC1, MLH1, MSH2, MSH6, and βiII-tubulin: Resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesotheliomaIn: Clinical Lung Cancer Jg. 14 (2013) Nr. 5, S. 558 - 567Online Volltext: dx.doi.org/
-
Early and locally advanced non-small-cell lung cancer (NSCLC) : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Jg. 24 (2013) Nr. Suppl. 6, S. vi89 - vi98Online Volltext: dx.doi.org/
-
Epidermal Growth Factor Receptor Inhibition in Lung Cancer : Status 2012In: Journal of Thoracic Oncology Jg. 8 (2013) Nr. 3, S. 373 - 384Online Volltext: dx.doi.org/
-
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. 15, S. 3076 - 3082Online Volltext: dx.doi.org/
-
Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatmentIn: British Journal of Cancer (BJC) Jg. 109 (2013) Nr. 5, S. 1223 - 1229Online Volltext: dx.doi.org/ (Open Access)
-
Free soluble HLA-G molecules but not exosome-derived soluble HLA-G molecules are of prognostic relevance in lung cancer patientsIn: Tissue Antigens Jg. 81 (2013) Nr. 5, S. 282 - 283Online Volltext: dx.doi.org/
-
Midterm changes in quality of life : A prospective evaluation after open pulmonary metastasectomyIn: The Annals of Thoracic Surgery Jg. 95 (2013) Nr. 3, S. 1006 - 1011Online Volltext: dx.doi.org/
-
Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten Medikamenten. Lunge, Niere, MelanomIn: Der Onkologe Jg. 19 (2013) Nr. 10, S. 821 - 834Online Volltext: dx.doi.org/
-
Neutrophils activate tumoral CORTACTIN to enhance progression of orohypopharynx carcinomaIn: Frontiers in Immunology Jg. 4 (2013) S. 33Online Volltext: dx.doi.org/ (Open Access)
-
Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy : A Multicenter Study of the Arbeitsgemeinschaft Internistische OnkologieIn: Oncology Jg. 84 (2013) Nr. 5, S. 284 - 289Online Volltext: dx.doi.org/
-
Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC)In: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. e19138Online Volltext: dx.doi.org/
-
Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancerIn: European journal of cancer Jg. 49 (2013) Nr. 11, S. 2461 - 2468Online Volltext: dx.doi.org/
-
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine : The TREAT studyIn: Annals of Oncology Jg. 24 (2013) Nr. 4, S. 986 - 992Online Volltext: dx.doi.org/
-
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexedIn: Journal of Thoracic Oncology Jg. 8 (2013) Nr. 1, S. 19 - 30Online Volltext: dx.doi.org/
-
Strategies for improving outcomes in NSCLC : A look to the futureIn: Lung Cancer Jg. 82 (2013) Nr. 3, S. 375 - 382Online Volltext: dx.doi.org/
-
A plasma proteomic signature predicts outcomes in a phase 3 study of Gemcitabine (G) plus Cisplatin (C) +/- sorafenib in first line stage IIIB or IV NSCLCIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 9, S. 407
-
Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexedIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 4, S. 766 - 767Online Volltext: dx.doi.org/ (Open Access)
-
Distribution pattern of metastases and their associations with survival of malignant pleural mesothelioma patients undergoing different treatment modalitiesIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 140
-
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer : analysis of data from the phase 3 FLEX studyIn: The Lancet Oncology Jg. 13 (2012) Nr. 1, S. 33 - 42Online Volltext: dx.doi.org/
-
EGFR mutation analysis from REASON : A registry for the epidemiologic and scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IVIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. Suppl. 15, S. e18016
-
EGFR mutation analysis from the German REASON study - a registry for the epidemiologic and scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IVIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 36
-
Effektivität und Toxizität von bildgeführter hochkonformaler Bestrahlung multipler zerebraler Metastasen mit/ohne Ganzhirnbestrahlung (WBRT) mittels helikaler TomotherapieIn: Strahlentherapie und Onkologie Jg. 188 (2012) Nr. 1 Suppl., S. 41 - 42Online Volltext: dx.doi.org/
-
Erste Sicherheitsanalyse der prospektiv-randomisierten multizentrischen ESPATÜ-Studie : Keine Signale für unerwartete Adverse Events/ToxizitätenIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 188 (2012) Nr. Suppl. 1, S. 34Online Volltext: dx.doi.org/
-
Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural MesotheliomaIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 9, S. 1440 - 1448Online Volltext: dx.doi.org/ (Open Access)
-
Frühes Stadium beim nichtkleinzelligen LungenkarzinomIn: Onkologie Jg. 35 (2012) Nr. Suppl. 3, S. 6 - 9Online Volltext: dx.doi.org/
-
Growth patterns of lung metastases from sarcoma : prognostic and surgical implications from histologyIn: Interactive Cardiovascular and Thoracic Surgery Jg. 15 (2012) Nr. 4, S. 612 - 617Online Volltext: dx.doi.org/
-
Improvement of histopathological Remission after neoadjuvant chemotherapy of accelerated hyperfractionation compared to conventional fractionation in locally advanced NSCLC (stage III)In: Strahlentherapie und Onkologie Jg. 188 (2012) Nr. Suppl. 1, S. 96 - 96
-
Increased effect of Aurora-B kinase inhibition on endoreplicated non-small lung cancer cell linesIn: Strahlentherapie und Onkologie Jg. 188 (2012) Nr. 1 Suppl., S. 115Online Volltext: dx.doi.org/
-
Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell linesIn: International Journal of Radiation Oncology, Biology, Physics Jg. 84 (2012) Nr. 2, S. 492 - 499Online Volltext: dx.doi.org/
-
Investigation of Folate Receptor alpha and Thymidylate Synthase Proteins Expression in metastatic Non-Small Cell Lung Cancer Patients treated with Pemetrexed-based ChemotherapyIn: Journal of Thoracic Oncology Jg. 7 (2012) Nr. 9, Suppl. 4, S. S211 - S212
-
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumorsIn: Clinical Cancer Research Jg. 18 (2012) Nr. 17, S. 4794 - 4805Online Volltext: dx.doi.org/ (Open Access)
-
Phase II trial of ptk787/zk 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage iiib/iv non-small-cell lung cancer (nsclc)In: Annals of Oncology Jg. 23 (2012) Nr. 3, S. 678 - 687Online Volltext: dx.doi.org/
-
Phase i open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumoursIn: Investigational New Drugs: The Journal of New Anticancer Agents Jg. 30 (2012) Nr. 5, S. 1962 - 1971Online Volltext: dx.doi.org/
-
Prognostic factors in patients with advanced non-small cell lung cancer : Data from the phase III FLEX studyIn: Lung Cancer Jg. 77 (2012) Nr. 2, S. 376 - 382Online Volltext: dx.doi.org/
-
Significance of Folate Receptor alpha (FRA) and Thymidylate Synthase (TS) expression in metastatic non-small cell lung cancer patients treated with pemetrexed-based chemotherapyIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 34
-
The gefitinib long-term responder (LTR) : a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)In: Lung Cancer Jg. 77 (2012) Nr. 1, S. 183 - 191Online Volltext: dx.doi.org/
-
VVTZ-Tumorprofil - First results of a preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer CenterIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 204 - 204
-
Βv-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancerIn: British Journal of Cancer (BJC) Jg. 107 (2012) Nr. 5, S. 823 - 830Online Volltext: dx.doi.org/ (Open Access)
-
"One-stop-shop" staging : should we prefer FDG-PET/CT or MRI for the detection of bone metastases?In: European Journal of Radiology Jg. 78 (2011) Nr. 3, S. 430 - 435Online Volltext: dx.doi.org/
-
10-year long-term survival (LTS) of induction (IND) chemotherapy (CTX) with three cycles cisplatin(P)/paclitaxel(T) followed by concurrent (CC) chemoradiation (CTX/RTX) P/Etoposide (ETO)/45 GY (1.5 GY BID) plus surgery (S) - A multicenter phase-II trial (Cistaxol)In: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S. 494
-
15-Year (very) long-term survival (VLTS) and competing risks (CR) analysis of induction (IND) chemotherapy (CTX) with three cycles cisplatin (P) / etoposide (E) followed by concurrent (CC) chemoradiation (CTX/RTX) PE/45 GY (1.5 GY BID) pkus surgery (S) = TRIMIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S.S 492 - S493
-
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancerIn: Annals of Oncology Jg. 22 (2011) Nr. 8, S. 1798 - 1804Online Volltext: dx.doi.org/ (Open Access)
-
Chemotherapy in Patients with Progressive, Undifferentiated Neuroendocrine Tumors : A Single-Center ExperienceIn: Hormone and Metabolic Research Jg. 43 (2011) Nr. 12, S. 838 - 843Online Volltext: dx.doi.org/
-
Combined modality treatment, especially concomitant chemoradiation : Which chemotherapy? Which Radiotherapy fractionation scheme?Toxicities?In: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S. S214 - S215
-
EGFR Mutation Status in NSCLC Patients Stage IIIB/IV in Germany -Initial Results From a German RegistryIn: European Journal of Cancer Jg. 47 (2011) Nr. Suppl. 1, S. S596Online Volltext: dx.doi.org/
-
Early and locally advanced diseaseIn: Lung Cancer Jg. 71 (2011) Nr. Suppl. 2, S. 2Online Volltext: dx.doi.org/
-
Effect of Aurora-B kinase inhibition on radiation induced cell-cycle checkpoint activation and cell death in non-small lung cancer cell linesIn: Strahlentherapie und Onkologie Jg. 187 (2011) Nr. Suppl. 1, S. 123
-
Evaluation of Betav-Tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancerIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. Suppl. 6, S. 1078
-
Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer (NSCLC)In: European Journal of Cancer (EJC) Jg. 47 (2011) Nr. Suppl. 4, S. 14
-
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy : A subgroup analysis of data from the FLEX phase 3 studyIn: The Lancet Oncology Jg. 12 (2011) Nr. 1, S. 30 - 37Online Volltext: dx.doi.org/
-
Hypofractionated image-guided radiotherapy (HF-IGRT) cerebral metastases by means of helical TomotherapyIn: Strahlentherapie und Onkologie Jg. 187 (2011) Nr. Suppl. 1, S. 19 - 19
-
Impact of dihydrofolate reductase expression for clinical benefit from pemetrexed in malignant pleural mesotheliomaIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. Suppl. 6, S. S1052 - S1053
-
Long-term survival (LTS) and competing risks within a prospective multi center German randomized trial comparing induction chemotherapy (CTx) followed by concurrent (cc) chemoradiation (CTx/RTx) plus surgery (SURG; TRIMODALITY) supplemented by PCI versus local treatment (Tx) alone (SURG + RTx) in operable IIIA NSCLC.In: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 7042Online Volltext: dx.doi.org/
-
Long-term survival (LTS) and competing risks within a prospective multicenter german randomized trial comparing induction (IND) chemotherapy (CTX) followed by concurrent (CC) chemoradiation (CTX/RTX) plus surgery (S) (= Trimodality) supplemented by PCI VEIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S. 495
-
Long-term survival (S) of induction chemotherapy (CTx) with three cycles cisplatin (cis)/paclitaxel (pac) followed by concurrent (cc) chemoradiation (CTx/RTx) cis/etoposide (eto) and 45 Gy (1.5 Gy bid) plus surgery (SURG) : Phase II results (CISTAXOL)In: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 7047Online Volltext: dx.doi.org/
-
Long-term survival results and prognostic factor analysis of two consecutive trimodality Phase-II trials in stage IIIA(N2) and selected stage IIIB non-small-cell lung cancer (NSCLC)In: Strahlentherapie und Onkologie Jg. 187 (2011) Nr. Suppl. 1, S. 68 - 69
-
MAGRIT phase III trial : MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLCIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. TPS210Online Volltext: dx.doi.org/
-
Multimodale Therapie des lokal-fortgeschrittenen nichtkleinzelligen LungenkarzinomsIn: Der Onkologe Jg. 17 (2011) Nr. 8, S. 691 - 701Online Volltext: dx.doi.org/
-
Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumorIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 3017Online Volltext: dx.doi.org/
-
Predictive value of thymidylate synthase and Folypoly-Glutamate Synthease for clinical benefit from pemetrexed in malignant pleural mesotheliomaIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. Suppl. 6, S. S1092 - S1093
-
Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesotheliomaIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 7024Online Volltext: dx.doi.org/
-
Prevention, diagnosis, therapy, and follow-up of lung cancer : interdisciplinary guideline of the German respiratory society and the German cancer society abridged versionIn: Pneumologie Jg. 65 (2011) Nr. 8, S. e51 - e75Online Volltext: dx.doi.org/
-
R1507, a monoclonal antibody to insulin-like growth factor receptor-1A (IGF-1R), in combination with erlotinib for advanced stage non-small cell lung cancer (NSCLC) : A placebo-controlled, randomized phase II studyIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S. 605
-
Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung CancerIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 34, S. 4574 - 4580Online Volltext: dx.doi.org/
-
Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung CancerIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 19, S. 2667 - 2674Online Volltext: dx.doi.org/
-
Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb) : TREATIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 7002Online Volltext: dx.doi.org/
-
Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC)In: Journal of Clinical Oncology Jg. 29 (2011) Nr. Suppl. 15, -Online Volltext: dx.doi.org/
-
Reason : a registry for the epidemiologic and scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV in GermanyIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. Suppl. 6, S. 1244
-
Reason : TKI sensitive EGFR mutation status and associated characteristics of advanced NSCLC patients - Results from a German registryIn: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 124 - 125
-
Safety Analysis of Patient Subgroups Defined by Low and High Tumour Epidermal Growth Factor Receptor (EGFR) Expression in FLEX Study Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy With or Without Cetuximab as First-Line TherapyIn: European Journal of Cancer Jg. 47 (2011) Nr. Suppl. 1, S. S598Online Volltext: dx.doi.org/
-
The Gefitinib Long-Term Responder (LTR) - a cancer stem-like cell story? : Insights from molecular analyses of German long-term responders treated in the iressa expanded access programIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. Suppl. 6, S. S966 - S967
-
Tumor epidermal growth factor receptor (EGFR) expression as a predictive biomarker of survival in FLEX study patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy plus cetuximab as first-line therapyIn: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 121
-
Very Late and Isolated Leptomeningeal Relapse of a Pulmonary Adenocarcinoma Presenting as DementiaIn: Onkologie Jg. 34 (2011) Nr. 6, S. 316 - 320Online Volltext: dx.doi.org/
-
First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab : Efficacy by histologyIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. Suppl. 15, S. 7556Online Volltext: dx.doi.org/
-
Grenzlinien der KurationIn: Oncology Research and Treatment Jg. 33 (2010) Nr. Suppl. 5, S. 12 - 20Online Volltext: dx.doi.org/ (Open Access)
-
Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trialIn: International Journal of Radiation Oncology, Biology, Physics Jg. 76 (2010) Nr. 3, S. 809 - 815Online Volltext: dx.doi.org/
-
Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancerIn: The Thoracic and Cardiovascular Surgeon Jg. 139 (2010) Nr. 6, S. 1424 - 1430Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patientsIn: Human Immunology Jg. 71 (2010) Nr. 5, S. 489 - 495Online Volltext: dx.doi.org/
-
Prävention, Diagnostik, Therapie und Nachsorge des LungenkarzinomsIn: Pneumologie Jg. 64 (2010) Nr. Suppl. 2, S. e1 - e164Online Volltext: dx.doi.org/
-
Use of a Continuous EGFR IHC Scoring Method Reveals Association between Tumor Response and ECFR Expression Levels for Patients Receiving Cetuximab plus CT versus CT Alone in the Phase III Trial FLEX in Advanced NSCLCIn: Journal of Thoracic Oncology Jg. 5 (2010) Nr. 12 Suppl. 7, S. S558 - S559Online Volltext: dx.doi.org/
-
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC) : a double-blind, randomised, phase 3 trialIn: The Lancet Oncology Jg. 11 (2010) Nr. 7, S. 619 - 626Online Volltext: dx.doi.org/
-
Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancerIn: Oncology Jg. 73 (2008) Nr. 5-6, S. 316 - 323Online Volltext: dx.doi.org/
-
Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumourIn: European Respiratory Journal Jg. 29 (2007) Nr. 1, S. 117 - 127Online Volltext: dx.doi.org/ (Open Access)
-
Value of ¹⁸F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapyIn: Clinical Cancer Research Jg. 12 (2006) Nr. 1, S. 97 - 106Online Volltext: dx.doi.org/
-
History Can Teach Us Something: Angiogenesis Inhibition RevisitedIn: Journal of Thoracic Oncology Jg. 19 (2024) Nr. 6, S. 849 - 851Online Volltext: dx.doi.org/
-
Too Good to be True?In: Journal of Thoracic Oncology Jg. 16 (2021) Nr. 4, S. 507 - 508Online Volltext: dx.doi.org/ (Open Access)
-
How should we choose the best therapy for elderly patients with stage III non-small-cell lung cancer?In: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 25, S. 2860 - 2862Online Volltext: dx.doi.org/
-
Staging of the Mediastinum : Are We Already There?In: Journal of Thoracic Oncology Jg. 8 (2013) Nr. 9, S. 1114 - 1115Online Volltext: dx.doi.org/
-
Compassionate use programs or phase IV trials of innovative molecular targeted drugs in lung cancer: Deal or no deal?In: Journal of Thoracic Oncology Jg. 5 (2010) Nr. 10, S. 1495 - 1497Online Volltext: dx.doi.org/ (Open Access)
-
68Ga-SSO-120 versus 18F-FDG PET in the Initial Staging of Small-Cell Lung Cancer PatientsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. Suppl. 1, Annual Congress of the European Association of Nuclear Medicine September 9–13, 2023 Vienna, Austria, S. 488 - S489Online Volltext: dx.doi.org/
-
68Ga-Satoreotide PET for Staging of Small-Cell Lung Cancer PatientsIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P165
-
Kreuzvalidierte Prognoseparameter C-reaktives Protein und Blutbild-Parameter im Verlauf der kurativ intendierten Radiochemotherapie bei Patienten mit nichtkleinzelligem Lungenkarzinom (NSCLC) im Stadium IIIA-CIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S100 - S101Online Volltext: dx.doi.org/ (Open Access)
-
Langzeitergebnisse nach hypofraktionierter ablativer Präzisionsbestrahlung bei Patienten mit multiplen cerebralen MetastasenIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S124Online Volltext: dx.doi.org/ (Open Access)
-
Langzeitüberleben und konkurrierende Risiken von Patienten einer randomisierten Studie zur defnitiven vs. neoadjuvanten Radiochemotherapie + Resektion mit einem nach der Induktion resektablen NSCLC im Stadium IIIIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S7 - S8Online Volltext: dx.doi.org/ (Open Access)
-
PCI in der metastasierten Situation beim SCLC in real world : Daten aus der Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S97Online Volltext: dx.doi.org/ (Open Access)
-
Real-world Daten zur Erhaltungstherapie mit Durvalumab nach defnitiver Strahlenchemotherapie bei Patienten mit Nicht-Kleinzelligem Lungenkarzinom in lokal fortgeschrittenen Stadien : Daten aus der Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S103Online Volltext: dx.doi.org/ (Open Access)
-
Testing for and frequency of EGFR and ALK alterations in patients with early and locally advanced non-small cell lung cancer in Germany : Results from the prospective German Registry CRISP (AIO-TRK-0315)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 10 - 11Online Volltext: dx.doi.org/ (Open Access) -
68GA-FAPI PET/CT in the evaluation of Non-Small Cell Lung Cancer (NSCLC)
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S107Online Volltext: dx.doi.org/ (Open Access) -
Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP) : Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315
ESMO Congress 2022, 9 - 13 September 2022, Paris, France and virtual,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S988Online Volltext: dx.doi.org/ (Open Access) -
EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315)In: Annals of Oncology Jg. 33 (2022) Nr. Suppl. 2, S. 54 - S55Online Volltext: dx.doi.org/ (Open Access)
-
Immune Checkpoint Inhibitor (ICI)-associated Pulmonary Manifestations (ICI-LM): Characterization of HRCT and BAL Findings
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie Jg. 76 (2022) Nr. Supplement 1, S. S52Online Volltext: dx.doi.org/ -
Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP) : Real-World Evidence zu NSCLC Patienten behandelt mit Radiochemotherapie in Deutschland - AIO-TRK-0315
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 269 - 270Online Volltext: dx.doi.org/ (Open Access) -
Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLCIn: Journal of Thoracic Oncology Jg. 17 (2022) Nr. 9, S. 65Online Volltext: dx.doi.org/
-
Robuste und lang-andauernde Wirksamkeit der Durvalumab-Konsolidierung bei NSCLC im Stadium III nach Induktionschemotherapie und definitiver Radiochemotherapie : Fokus auf Behandlungsauswahl und prognostische Faktoren
28. Kongress der Deutschen Gesellschaft für Radioonkologie ; DEGRO 2022 ; 26. bis 28.05.2022, Stuttgart, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 198 (2022) Nr. Supplement 1, S. S15Online Volltext: dx.doi.org/ (Open Access) -
Bronchoalveolar lavage fluid (BALF) findings in patients with immune checkpoint inhibitor (ICI)-associated interstitial pneumonia (IP)In: European Respiratory Journal (ERJ) (2021) OA4240Online Volltext: dx.doi.org/
-
Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP Registry real-world cohort (AIO-TRK-0315)
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 111Online Volltext: dx.doi.org/ (Open Access) -
Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315)In: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. S1015 - S1016Online Volltext: dx.doi.org/ (Open Access)
-
Clinical Platform for Research into molecular Testing, Treatment and Disease Progression in Patients with Lung Cancer (CRISP) : First Real-World Evidence on Stage II and III NSCLC in Germany - AIO-TRK-0315In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. S11 - S12
-
Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma patients (CRISP) : First real-world evidence of NSCLC Stage II and III in Germany - AIO-TRK-0315
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 3Online Volltext: dx.doi.org/ (Open Access) -
Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP) : First real-world evidence of NSCLC stage II and III in Germany - AIO-TRK-0315In: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. S935 - S936Online Volltext: dx.doi.org/ (Open Access)
-
Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapyIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9050 - 9050Online Volltext: dx.doi.org/
-
EBUS-TBNA and [F-18] FDG-PET/CT for precise Target Volume Definition prior to Chemoradiotherapy : Lymphonodular Spreading Patterns in Stage III NSCLCIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 142
-
Image-guided ablative Radiotherapy for Patients with multiple cerebral Metastases using Precision helical IrradiationIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 183
-
Re-Irradiation of cerebral Metastases after prophylactic Brain Skull irradiation in small-cell neuroendocrine Lung Cancer (SCLC)In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 176
-
Evaluation der Korrelation des anatomischen und funktionellen CT-Ventilations- und SPECT-Perfusions-Lungenvolumens bei Patienten mit Nicht-kleinzelligem Lungenkarzinom
26. Jahrestagung der Deutschen Gesellschaft für Radioonkologie (DEGRO) ; 24. Juni - 28. Juni 2020, Wiesbaden, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 196 (2020) Nr. 1 Supplement: Abstracts DEGRO 2020, S. S145 - S146Online Volltext: dx.doi.org/ (Open Access) -
How does the SarsCov2 epidemic the treatment of patients with lung cancer in Germany? : Data from the prospective CRISP registry
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 137Online Volltext: dx.doi.org/ (Open Access) -
Lymphknoten-Staging von lokal fortgeschrittenen, nicht kleinzelligen Lungenkarzinomen (NSCLC) : Wert von [18F] FDG-PET/CT und EBUS/TBNA zur Festlegung des Zielvolumens bei definitiver Radiotherapie in kurativer Intention
26. Jahrestagung der Deutschen Gesellschaft für Radioonkologie (DEGRO) ; 24. Juni - 28. Juni 2020, Wiesbaden, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 196 (2020) Nr. 1 Supplement: Abstracts DEGRO 2020, S. S143Online Volltext: dx.doi.org/ (Open Access) -
Optimierung prognostischer Modelle für das Überleben von Patienten mit lokal fortgeschrittenen kleinzelligen Lungenkarzinomen nach definitiver Radiochemotherapie mittels künstlicher Intelligenz
26. Jahrestagung der Deutschen Gesellschaft für Radioonkologie (DEGRO) ; 24. Juni - 28. Juni 2020, Wiesbaden, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 196 (2020) Nr. 1 Supplement: Abstracts DEGRO 2020, S. S57 - S58Online Volltext: dx.doi.org/ (Open Access) -
Patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) show highly favorable outcomes with treatment sequences provided at a comprehensive cancer center
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 137Online Volltext: dx.doi.org/ (Open Access) -
Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany : Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.; 25.–28. März 2020 (verschoben auf 2021), Leipzig,In: Pneumologie Jg. 74 (2020) Nr. Suppl. 1, S. S127Online Volltext: dx.doi.org/ -
Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany : Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315)
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.; 25.–28. März 2020 (verschoben auf 2021), Leipzig,In: Pneumologie Jg. 74 (2020) Nr. Suppl. 1, S. S132Online Volltext: dx.doi.org/ -
Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany : Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.; 25.–28. März 2020 (verschoben auf 2021), Leipzig,In: Pneumologie Jg. 74 (2020) Nr. Suppl. 1, S. S15 - S16Online Volltext: dx.doi.org/ -
Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C
ESMO Virtual Congress 2020, 19 – 21 September / 16 – 18 October 2020,In: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S872Online Volltext: dx.doi.org/ (Open Access) -
Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 135Online Volltext: dx.doi.org/ (Open Access) -
Welche Standard-PTV-Säume werden bei gegateter Strahlentherapie in Exspiration bei lokal fortgeschrittenen Lungenkarzinomen nach online-Navigation benötigt?
26. Jahrestagung der Deutschen Gesellschaft für Radioonkologie (DEGRO) ; 24. Juni - 28. Juni 2020, Wiesbaden, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 196 (2020) Nr. 1 Supplement: Abstracts DEGRO 2020, S. S58Online Volltext: dx.doi.org/ (Open Access) -
Defects in Homologous Recombination Repair Indicates Susceptibility for Olaparib Treatment in Malignant Pleural MesotheliomaIn: Journal of Thoracic Oncology Jg. 14 (2019) Nr. 10, Supplement, S. S482Online Volltext: dx.doi.org/ (Open Access)
-
Immunohistochemically Detectable Metallothionein Expression in Malignant Pleural Mesotheliomas is Strongly Associated with Early Failure to Platin-Based Chemotherapy
Herbsttagung der Sektion Zellbiologie in der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V., Essen, 09.–10.11.2018,In: Pneumologie Jg. 73 (2019) Nr. 02, S. 110 - 111Online Volltext: dx.doi.org/ -
Influence of Methallothionein Expression on Sensitivity Against Platin Compounds in Human Malignant Pleural Mesothelioma Cell Lines – Knock-Down of Gene Expression as New Therapeutic Approach?
Herbsttagung der Sektion Zellbiologie in der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V., Essen, 09.–10.11.2018,In: Pneumologie Jg. 73 (2019) Nr. 02, S. 115Online Volltext: dx.doi.org/ -
Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany : treatment and first outcome from the prospective German registry platform CRISP (AIO-TRK-0315)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 113Online Volltext: dx.doi.org/ (Open Access) -
Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany : Treatment and first outcome from the prospective German registry platform CRISP (AIO-TRK-0315)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 109Online Volltext: dx.doi.org/ (Open Access) -
Patients with metastatic non-small cell lung carcinoma and targetable oncogenic molecular alterations in Germany : Treatment and first outcome data from the prospective German registry CRISP (AIO-TRK-0315)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 107Online Volltext: dx.doi.org/ (Open Access) -
Processing Escapes : an Alternative Explanation for Immune Therapy Resistance
Herbsttagung der Sektion Zellbiologie in der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V., Essen, 09.–10.11.2018,In: Pneumologie Jg. 73 (2019) Nr. 02, S. 111 - 112Online Volltext: dx.doi.org/ -
Processing Escapes : Novel Resistance Mechanisms Under Immune Checkpoint Inhibition in NSCLCIn: Journal of Thoracic Oncology Jg. 14 (2019) Nr. 10, Supplement, S. S450Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic Value of Metabolic Tumor Volume after Induction Chemotherapy in Stage IIIA/B Non-Small-Cell Lung Cancer : Secondary Analysis of a Randomized Phase 3 Trial
61st Annual Meeting of the American Society for Radiation Oncology ; September 15-18, 2019, Chicago, IL, USA,In: International Journal of Radiation Oncology, Biology, Physics Jg. 105 (2019) Nr. 1, Supplement, S. S146 - S147Online Volltext: dx.doi.org/ (Open Access) -
Development of predictors for PD-1/PD-L1-directed therapy of non-small cell lung cancer (NSCLC) by gene expression profiling of small diagnostic biopsies (DBX)In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 15 Suppl., S. e15121Online Volltext: dx.doi.org/ (Open Access)
-
Long-term Survival (LT-S) and Survivorship Program (SS-P) of Lung Cancer (LC) Patients (Pts) - B : Implications for Follow-up (F-up) and Surveillance (SV)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 109 - 110Online Volltext: dx.doi.org/ (Open Access) -
Long-term Survival(LTS) and Survivorship Program(SS-P) of Lung Cancer(LC) Patients(Pts). Investigations(Invest) on LT-toxicities(Tox) and late morbidities(Morb)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 108Online Volltext: dx.doi.org/ (Open Access) -
Molecular testing, frequency of molecular alterations and first-line treatment of patients with non-small cell lung carcinoma (NSCLC) in Germany : First results from the prospective German Registry CRISP (AIO-TRK-0315)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 17 - 17Online Volltext: dx.doi.org/ (Open Access) -
Molecular testing, frequency of molecular alterations and targeted 1st-line treatment of patients with non-small cell lung carcinoma in Germany : First results from the prospective German Registry CRISP (AIO-TRK-0315)In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. e21236 - e21236Online Volltext: dx.doi.org/ (Open Access)
-
POSEIDON : A phase 3 study of first-line Durvalumab +/- Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; Wien, 28. September - 2. Oktober 2018,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 295Online Volltext: dx.doi.org/ (Open Access) -
Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany : Results from the prospective German registry CRISP (AIO-TRK-0315)In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii515Online Volltext: dx.doi.org/ (Open Access)
-
Vergleich der 3D-Navigation der atemabhängigen Tumor-Position mittels stereoskopischer Röntgenaufnahmen (ExacTrac) bzw. kV-ConeBeam-CTs bei der kurativen Radiotherapie von Lungenkarzinomen
23. Jahrestagung der Deutschen Gesellschaft für Radioonkologie ; DEGRO 2017 ; 14. - 18. Juni 2017, Berlin, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 193 (2017) Nr. Suppl. 1: Abstracts DEGRO 2017, S. S79 - S80Online Volltext: dx.doi.org/ -
Clinical Outcome of Targeted Therapy with Gefitinib in Metastatic NSCLC Depending on the Type of EGFR Mutation : A REASON Subgroup Analysis by Exon
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 120Online Volltext: dx.doi.org/ -
REASON : Factors influencing outcome in patients (pts) with NSCLC stage IIIB/IV and mutated EGF receptor (EGFR-M plus ) treated with gefitinib
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 120Online Volltext: dx.doi.org/ -
18 F-FDG-Response als prognostischer Faktor für das progressionsfreie Überleben bei der Behandlung von lokal fortgeschrittenen, nichtkleinzelligen Lungenkarzinonem : Trimodale Therapie vs. definitive Radiochemotherapie – Monozentrische Ergebnisse
21. Jahrestagung der Deutschen Gesellschaft für Radioonkologie, 25. Juni 2015, Hamburg,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 191 (2015) Nr. Suppl.1, S. S21 - S22Online Volltext: dx.doi.org/ -
Ganzhirnbestrahlung (WBRT) versus Ganzhirnbestrahlung mit bildgeführter stereotaktischer Bestrahlung multipler cerebraler Metastasen mittels helikaler Tomotherapie – Toxizitätsanalyse einer randomisierten Studie
21. Jahrestagung der Deutschen Gesellschaft für Radioonkologie, 25. Juni 2015, Hamburg,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 191 (2015) Nr. Suppl.1, S. 149Online Volltext: dx.doi.org/ -
Hirnmetastasen bei Patienten mit lokal fortgeschrittenem NSCLC nach multimodaler kurativer Therapie in einem randomisierten Protokoll : prognostische Faktoren
21. Jahrestagung der Deutschen Gesellschaft für Radioonkologie, 25. Juni 2015, Hamburg,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 191 (2015) Nr. Suppl. 1, S. 36 - 37Online Volltext: dx.doi.org/ -
Randomized study of individualized, pharmacokinetically-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,In: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 5, S. 14 - 14Online Volltext: dx.doi.org/ -
Rekursive Partitions-Analyse prognostischer Faktoren für das Langzeit-Überleben nach trimodaler Therapie von Patienten mit lokal fortgeschrittenem NSCLC
21. Jahrestagung der Deutschen Gesellschaft für Radioonkologie, 25. Juni 2015, Hamburg,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 191 (2015) Nr. Suppl. 1, S. 23Online Volltext: dx.doi.org/ -
A multi-center phase II study investigating the combination of RAD001 (everolimus) with paclitaxel and carboplatin in first line treatment of patients with advanced Large Cell Lung Cancer with Neuroendocrine Differentiation (LCNEC) - a case report
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 88Online Volltext: dx.doi.org/ -
Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC) : RADIANT Results: Locally Advanced Non-Small Cell Lung Cancer
2014 Chicago Multidisciplinary Symposium in Thoracic Oncology ; 30 October-1 November 2014, Chicago, Illinois, USA,In: International Journal of Radiation Oncology, Biology, Physics Jg. 90 (2014) Nr. 5, Supplement, S. S2 - S3Online Volltext: dx.doi.org/ -
Case report from a patient with a histology shift from large cell neuroendocrine carcinoma of the lung (LCNEC) to small cell lung cancer (SCLC) after first line treatment in a trial investigating everolimus combined with paclitaxel and carboplatin
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 68 - 69Online Volltext: dx.doi.org/ -
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 226 - 227Online Volltext: dx.doi.org/ -
Correlation of proteomics and first-line platinum-based chemotherapy in stage NSCLC in a large single-center cohort
50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30-June 3, 2014, Chicago, Illinois, USA,In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl.,Online Volltext: dx.doi.org/ -
Definitive Hyperfractionated Accelerated (AHF) Radiochemotherapy (CRT) Versus Neoadjuvant AHF-CRT and Surgery (S) for Patients (pts) With Operable Stage IIIA(N2)/Selected IIIB Non-small-Cell Lung Cancer (NSCLC) Following Induction Chemotherapy (IND-C) : Results From a Multicenter Phase III Study
56th Annual Meeting of the American Society for Radiation Oncology ; 14-17 September 2014, San Francisco, CA, USA,In: International Journal of Radiation Oncology, Biology, Physics Jg. 90 (2014) Nr. 1, Supplement, S. S146 - S147Online Volltext: dx.doi.org/ -
Definitive accelerated-hyperfractionated (AHF) Chemoradiotherapy (CRT) vs. neoadjuvant AHF-CRT and Surgery (S) for Patients with operable NSCLC in Stage IIIA(N2)/IIIB after Induction Chemotherapy (IND-C) : Results of a randomized Multicentre Study
20. Jahreskongress der Deutschen Gesellschaft für Radioonkologie (DEGRO), 3. bis 6. Juli 2014, Düsseldorf,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 190 (2014) Nr. Suppl. 1, S. 5 - 6Online Volltext: dx.doi.org/ -
Final Results from REASON, a Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV in GermanyIn: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 89Online Volltext: dx.doi.org/
-
Neoadjuvant Docetaxel/Cisplatin/5-FU based radiochemotherapy (RT-CT) increases pathologic complete remissions and survival of patients with locally advanced oral cavity carcinomas in comparison to RT-CT with cisplatin alone followed by resection – a long term observational study
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl.1, S. 79Online Volltext: dx.doi.org/ -
P6-9 Neoadjuvante Radiochemotherapie beim lokal fortgeschrittenen Mundhöhlenkarzinom : Vergleich der Langzeitergebnisse zweier Protokolle
20. Jahreskongress der Deutschen Gesellschaft für Radioonkologie (DEGRO), 3. bis 6. Juli 2014, Düsseldorf,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 190 (2014) Nr. Suppl.1, S. 99 - 100Online Volltext: dx.doi.org/ -
Prognostisches Modell für das Langzeit-Überleben von Patienten mit lokal fortgeschrittenem nicht-kleinzelligen Lungenkarzinom (NSCLC) nach neoadjuvanter Radiochemotherapie (RT/CT) und Resektion
20. Jahreskongress der Deutschen Gesellschaft für Radioonkologie (DEGRO), 3. bis 6. Juli 2014, Düsseldorf,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 190 (2014) Nr. Suppl 1, S. 17Online Volltext: dx.doi.org/ -
TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 92Online Volltext: dx.doi.org/ -
TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutationIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, Suppl., S. 8109Online Volltext: dx.doi.org/
-
Vergleich von pCR und mediastinalem Downstaging als Surrogat- Marker für das Langzeit-Überleben von Patienten mit lokal fortgeschrittenem nicht-kleinzelligen Lungenkarzinom (NSCLC) nach neoadjuvanter Radiochemotherapie (RT/CT) und Resektion (Trimodalität)
20. Jahreskongress der Deutschen Gesellschaft für Radioonkologie (DEGRO), 3. bis 6. Juli 2014, Düsseldorf,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 190 (2014) Nr. Suppl. 1, S. 17Online Volltext: dx.doi.org/ -
WTZ-Tumorprofil-A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center : Two years experience
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 2 - 3Online Volltext: dx.doi.org/ -
A multi-centric, open-label, phase II study investigates the combination of RAD001 (everolimus) with paclitaxel and carboplatin in first line treatment of patients with advanced (stage IV) Large Cell Lung Cancer with Neuroendocrine Differentiation (LCNEC)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 252Online Volltext: dx.doi.org/ -
Akzeleriert-hyperfraktionierte Radiotherapie (RTx) mit simultaner Chemotherapie (CTx) im neoadjuvanten Konzept bei Stadium-III-Lungenkarzinom : signifikant höhere Rate pathologisch kompletter Remissionen (pCR) im Vergleich mit konventioneller Fraktionierung
19. Jahreskongress der Deutschen Gesellschaft für Radioonkologie Berlin, 9. bis 12. Mai 2013,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 189 (2013) Nr. Suppl. 1, S. 19Online Volltext: dx.doi.org/ -
Akzelerierte Post-Pneumonektomie Salvage-Bestrahlung (RTx) mit simultaner Chemotherapie (CTx) bei Patienten mit kontralate - ralen zentralen Lungenkarzinomrezidiven
DEGRO 2013 19. Jahreskongress der Deutschen Gesellschaft für Radioonkologie Berlin, 9. bis 12. Mai 2013,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 189 (2013) Nr. Suppl. 1, S. 67Online Volltext: dx.doi.org/ -
Compliance-Analyse der prospektiv-randomisierten multizentrischen ESPATÜ-Studie – lassen sich Patienten lieber operieren?
19. Jahreskongress der Deutschen Gesellschaft für Radioonkologie Berlin, 9. bis 12. Mai 2013,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 189 (2013) Nr. Suppl. 1, S. 87Online Volltext: dx.doi.org/ -
Pathologic complete remission after induction chemotherapy and intercalated Erlotinib in EGFR-mutated adenocarcinoma stage IIIA : Case report
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 253 - 254Online Volltext: dx.doi.org/ -
Pathologic complete remission after induction chemotherapy and intercalated erlotinib in EGFR-mutated adenocarcinoma stage IIIA : CASE REPORT
15th World Conference on Lung Cancer, October 27 - 30 2013, Sydney, Australia,In: Journal of Thoracic Oncology Jg. 8 (2013) Nr. Suppl. 2, S. S1169 - S1170Online Volltext: dx.doi.org/ -
Prä-therapeutische ex-vivo Reparatur Kinetiken von Cisplatin-DNA-Addukten in Zirkulierenden Tumorzellen als Platin-Resistenz Test
119. Kongress der Deutschen Gesellschaft für Innere Medizin e.V., 06. - 09. April 2013, Wiesbaden,In: Der Internist Jg. 54 (2013) Nr. Suppl. 1, S. 95 - 96Online Volltext: dx.doi.org/ -
TRY : A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutationIn: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 30Online Volltext: dx.doi.org/
-
Tecemotide (L-BLP25) in unresectable stage III non-small cell lung cancer in the phase III start study : Further endpoint and exploratory biomarker results
15th World Conference on Lung Cancer, October 27 - 30 2013, Sydney, Australia,In: Journal of Thoracic Oncology Jg. 8 (2013) Nr. Suppl. 2, S. S135 - S136Online Volltext: dx.doi.org/ -
Try : a phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutationIn: Journal of Thoracic Oncology Jg. 8 (2013) Nr. Suppl. 2, S. S914 - S915Online Volltext: dx.doi.org/ (Open Access)
-
Vergleich einer neoadjuvanten Radiochemotherapie mit Docetaxel/Cisplatin/5-FU oder mit Cisplatin alleine beim lokal fortgeschrittenen Mundhöhlenkarzinom
19. Jahreskongress der Deutschen Gesellschaft für Radioonkologie Berlin, 9. bis 12. Mai 2013,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 189 (2013) Nr. Suppl. 1, S. 100Online Volltext: dx.doi.org/ -
Accelerated Hyperfractionated Radiation Therapy Within Trimodality Therapy Concepts for Stage IIIa/b Non-small Cell Lung Cancer : Markedly Higher Rate of Pathologic Complete Remissions Than With Conventionally Fractionated Radiochemotherapy
54th Annual Meeting of the American Society for Radiation Oncology ; 28-31 October 2012, Boston, MA, USA,In: International Journal of Radiation Oncology, Biology, Physics Jg. 84 (2012) Nr. 3, Supplement, S. S154Online Volltext: dx.doi.org/ -
Einfluss der Induktions-Chemotherapie auf die Parameter der hochdosierten Radiochemotherapie beim lokal fortgeschrittenen LungenkarzinomIn: Strahlentherapie und Onkologie Jg. 188 (2012) Nr. 1 Suppl., S. 96Online Volltext: dx.doi.org/
-
Folylpoly-α-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in advanced non-small cell lung cancer (NSCLC)In: Cancer Research Jg. 72 (2012) Nr. 8, Suppl., S. 1713Online Volltext: dx.doi.org/
-
Impact of EGFR mutation status on clinical benefit from BIBW 2992 in patients (PTS) with advanced non-small lung cancer (NSCLC) progressing after chemotherapy (CTX) and erlotinib (E) or gefitinib (G) : a single center experience
37th ESMO Congress, 28 September - 2 October 2012, Vienna, Austria,In: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 9, S. 437 - 438Online Volltext: dx.doi.org/ -
Neoadjuvante Therapie beim lokal fortgeschrittenen Mundhöhlenkarzinom : Induktionschemotherapie mit Docetaxel/Cisplatin/5-FU gefolgt von simultaner Strahlentherapie plus Docetaxel/Cisplatin gefolgt von OP – Phase-I-Studie: Ergebnisse und 3J-FUIn: Strahlentherapie und Onkologie Jg. 188 (2012) Nr. 1 Suppl., S. 90 - 90Online Volltext: dx.doi.org/
-
Postpneumonectomy Radical Accelerated (Re-)irradiation and Concurrent Chemotherapy for Patients With Contralateral Central Lung Cancer Relapses
54th Annual Meeting of the American Society for Radiation Oncology ; 28-31 October 2012, Boston, USA,In: International Journal of Radiation Oncology, Biology, Physics Jg. 84 (2012) Nr. 3, Supplement, S. S598Online Volltext: dx.doi.org/ -
Competing risks analysis and long-term survival (LTS) of patients (PTS) with locally advanced (LAD) stage III non-small- cell lung cancer (NSCLC) treated on sequential trimodality (TM) trials
14th World Conference on Lung Cancer (WCLC), July 03 - 07, 2011, Amsterdam, The Netherlands,In: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S. S376 - S377 -
Mutation Testing and First Line Treatment of Patients With Advanced NSCLC and Positive EGFR Mutation Status – Results From a German RegistryIn: European Journal of Cancer Jg. 47 (2011) Nr. Suppl. 1, S. S636Online Volltext: dx.doi.org/
-
1stCycle rash as a Clinical Marker of outcome in Patients with advanced Non-Small Cell Lung Cancer (NSCLC) receiving 1st-Line Chemotherapy (CT) plus Cetuximab : Analysis by Histology
35th ESMO (European Society for Medical Oncology) Congress. Milan, Italy. October 8-12, 2010,In: Annals of Oncology Jg. 21 (2010) Nr. Suppl. 8, S. 131 - 132 -
ASA404 (a Tumor-VDA) in advanced solid tumors : an update on clinical trials
29. Deutscher Krebskongress. Berlin 24.-27. Februar 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 2, S. 154 - 154Online Volltext: dx.doi.org/ -
Baseline population description of the German patient population in the EPICLIN-Lung epidemiological study in Non-Small Cell Lung Cancer (NSCLC) across Europe
29. Deutscher Krebskongress. Berlin 24.-27. Februar 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 2, S. 129 - 130Online Volltext: dx.doi.org/ -
Increased Thymidylate Synthase (TS) Gene Copy Number in NSCLCIn: Journal of Thoracic Oncology Jg. 5 (2010) Nr. 5 Suppl. 1, S. S56Online Volltext: dx.doi.org/
-
Neoadjuvant therapy in stage III
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 7, S. 102 - 103Online Volltext: dx.doi.org/ -
Peritoneal mesothelioma
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 12 - 13Online Volltext: dx.doi.org/ -
Safety of First-Line Bevacizumab (BV)-Based Therapy in the Sail (MO19390) Trail : Central Tumour Locazion (CTL) and Hypertension (HTN) in Patients (PTS) with advanced Non-Small Cell Lung Cancer (NSCLC)
35th ESMO Congress, Milan, Italy 8–12 October 2010,In: Annals of Oncology Jg. 21 (2010) Nr. Suppl. 8, S. 144 -
Targeted therapy for patients with thyroid cancer
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 214Online Volltext: dx.doi.org/ -
The gefitinib Long-Term Survivor (LTS) - a species on its own? : Molecular and clinico-pathological characteristics of German Long-Term Survivors treated in the Iressa Expanded Access Program (EAP)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 1.–5. Oktober 2010, Berlin,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 103 - 103Online Volltext: dx.doi.org/ -
Use of ERCC1 expression levels in circulating tumor cells to predict to response to platinum-based chemotherapy in patients with non-small cell lung cancer
2010 ASCO Annual Meeting, June 4-8, 2010, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. 15, Suppl., 7512 -
Stage iiib non-small cell lung cancerIn: Principles and Practice of Lung Cancer: The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC) / Pass, Harvey I. (Hrsg.) 2012, S. 821 - 836
-
Oligometastatic non-small cell lung cancer : Impact of local and systemic treatment approaches on clinical outcome
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S828Online Volltext: dx.doi.org/ -
Patient-reported outcomes vor und während der COVID-19-Pandemie bei Patienten mit lokal fortgeschrittenem oder metastasiertem nicht-kleinzelligen Lungenkarzinom in Deutschland : Daten aus der prospektiven CRISP Registerplattform (AIO-TRK-0315)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 127Online Volltext: dx.doi.org/ (Open Access) -
Decrease of circulating tumor cells associates with response to platinum-based chemotherapy in patients with non-small cell lung cancer, but not with small cell lung cancer
14th World Conference on Lung Cancer (WCLC), July 03 - 07, 2011, Amsterdam, The Netherlands,In: Journal of Thoracic Oncology Jg. 6 (2011) Nr. 6, Suppl. 2, S. S1114